Phase II clinical trials of Oxford COVID-19 vaccine begin in Chennai & Pune


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Phase II clinical trials of Oxford COVID-19 vaccine begin in Chennai & Pune
After, Covishield's first shot, tests related to COVID-19 and antibodies came negative, officials said

Second Phase clinical trials of Oxford COVID-19 vaccine begin in Chennai and Pune. In Chennai, two prominent medical institutions are starting the second and third phase field trial of the Oxford vaccine candidate Covishield.

In another development, the Tamil Nadu Government has exempted college students having arrears except in the last semester from writing the examinations, in view of Covid-19. Previously the exemption has been made for the regular students.

Meanwhile, the total number of COVID-19 infections in the state is nearing the four lakh mark. 5958 people were tested positive yesterday taking the total to over 3,97000. However, the active caseload in the state is about 52 thousand.

Chennai is one of the seventeen locations in India to conduct the field trial of the promising vaccine candidate Covishield, developed jointly by the Oxford University and AstraZeneca. The Government Rajiv Gandhi General Hospital and the Sri Ramachandra Institute of Higher Education and Research are the two institutions in the city that run the trial.

The state director of public health Dr TS Selva Vinayagam, who coordinates the study in Chennai, told , healthy volunteers above the age of 18 are being involved in its multi-centric clinical trial. Dr TS Selva Vinayagam, Director, Public Health said, “We will be starting the Phase-2 and Phase-3 together. We will be following the volunteers for up to 180 days. This is to assess the safety, immunogenicity and reacto-genecity. We will be doing that.” The T-cells in the white blood corpuscles against the viral pathogen are said to be observed in 14-days after administering the vaccine and the antibodies in about 28 days. Their effectiveness to eliminate the virus and several other factors will be exhaustively tested during the trial.In Maharashtra, the Phase II clinical trial of the Oxford COVID-19 vaccine, being manufactured by the Serum Institute of India (SII), began at a medical college and hospital in Pune today. According to the Hospital officials, two male volunteers were administered the vaccine at Bharati Vidyapeeth's Medical College and Hospital post noon today.

Our correspondent reports, doctors at Bharati Vidyapeeth's Medical College and Hospital administered the first shot of the 'Covishield' vaccine to a 32-year-old man after his reports of COVID-19 and antibodies tests came out negative. Another 48-year-old male volunteer was also given the vaccine. According to details by the Medical Director of Bharati Vidyapeeth's Medical College Hospital and Research Centre, Dr Sanjay Lalwani, the COVID-19 and antibodies tests were conducted on the five volunteers.

Of them, the reports of three volunteers' antibodies test came out positive so they became ineligible for today's trial. The doctor informed that in all, 25 candidates will be given the vaccine in next seven days. Meanwhile, the Sangli district administration has initiated stringent action on the private hospitals which are asking to deposit advanced amount before admitting Covid positive patients. The Sangli district collector, Dr. Abhijit Choudhari said that the private hospitals cannot ask a patient to deposit advanced amount before his admission to the hospital.

Tags : #Covishield #OxfordVaccine #SerumInstitute #Pune #Chennai #Phase2trialCovidvaccine #OxfordVaccinePhase2Trial #CovishieldPhase2Trial #Astrazeneca #LatestCovidNewsAug27

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026